newsfilter
← Latest News
PR Newswire·

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Ends Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 LEXINGTON, Mass., May 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies